Somatrogon (Long-Acting Growth Hormone) from Canada
Somatrogon is a long-acting structural analogue of somatotropin created by linking human growth hormone to a CTP (C-terminal peptide) sequence from hCG beta subunit. This modification extends its half-life for weekly dosing in growth hormone deficiency. Classified in HTS 2937.11.00.00 as a chain-modified polypeptide analogue used primarily as a hormone.
Duty Rate — Canada → United States
100%
Rate breakdown
9903.04.60100%Pharmaceuticals: patented pharma articles — 100% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Submit sequence analysis confirming CTP modification for chain-modified polypeptide classification
• Maintain validated cold chain (2-8°C) with temperature monitoring records
• Avoid bulk packaging declarations that might suggest non-hormonal protein status